Session Detail


Session Title: Biomarker Driven Clinical Trials
Session Type: Clinical Trials Symposium
Session Start/End Time: Monday, Apr 07, 2014, 10:30 AM -12:30 PM
Location: Room 29, San Diego Convention Center
CME: CME-Designated
CME/CE Hours: 2
Presentations:
Chairperson
Monday, Apr 07, 2014, 10:30 AM -12:30 PM
David S. Hong. UT MD Anderson Cancer Ctr., Houston, TX
CT227: Neratinib plus standard neoadjuvant therapy for high-risk breast cancer: Efficacy results from the I-SPY 2 TRIAL
Monday, Apr 07, 2014, 10:30 AM -10:50 AM
John W. Park1, Minetta C. Liu2, Douglas Yee3, Angela DeMichele4, Laura van 't Veer1, Nola Hylton1, Fraser Symmans5, Meredith B. Buxton1, A. Jo Chien1, Amy Wallace6, Michelle Melisko1, Richard Schwab7, Judy Boughey2, Debashish Tripathy8, Hank Kaplan9, Rita Nanda10, Stephen Chui11, Kathy S. Albain12, Stacy Moulder5, Anthony Elias13, Julie E. Lang14, Kirsten Edminston15, Donald Northfelt16, David Euhus17, Qamar Khan18, Julia Lyandres1, Sarah E. Davis1, Christina Yau1, Ashish Sanil19, Laura J. Esserman1, Donald A. Berry20. 1UCSF, San Francisco, CA; 2Mayo Clinic, Rochester, MN; 3University of Minnesota, Minneapolis, MN; 4University of Pennsylvania, Philadelphia, PA; 5MD Anderson Cancer Center, Houston, TX; 6University of California San Diego, CA; 7University of California San Diego, San Diego, CA; 8University of Southern California, Los Angeles, CA; 9Swedish Medical Center, Seattle, WA; 10University of Chicago, Chicago, IL; 11Oregon Health & Sciences University, Portland, OR; 12Loyola University, Chicago, IL; 13University of Denver, Denver, CO; 14University of Southern California, CA; 15Inova Fairfax Hospital, Falls Church, VA; 16Mayo Clinic, Scottsdale, AZ; 17UT Southwestern Medical Center, Dallas, TX; 18University of Kansas, Lawrence, KS; 19Berry Consultants, Austin, TX; 20Berry Consultants, TX
Discussant
Monday, Apr 07, 2014, 10:50 AM -11:00 AM
Lajos Pusztai. Yale University Medical School, New Haven, CT
CT228: A phase II study of afatinib (A) in patients (pts) with metastatic human epidermal growth factor receptor (HER2)-positive trastuzumab (T) refractory esophagogastric (EG) cancer.
Monday, Apr 07, 2014, 11:00 AM -11:20 AM
Yelena Y. Janjigian, Tooba Imtiaz, David H. Ilson, David B, Solit, Michael F. Berger, Efsevia Vakiani. MSKCC, New York, NY
Discussant
Monday, Apr 07, 2014, 11:20 AM -11:30 AM
Jordan D. Berlin. Vanderbilt-Ingram Cancer Ctr., Nashville, TN
CT229: A phase II and biomarker study of an irreversible pan-human EGF receptor (HER) tyrosine kinase inhibitor, dacomitinib, in patients with recurrent and/or metastatic squamous cell carcinoma of head and neck (R/M-SCCHN)
Monday, Apr 07, 2014, 11:30 AM -11:50 AM
Han Sang Kim1, Hyung Joo Kwon2, Myung-Ju Ahn3, Byung Woog Kang4, Jong-Mu Sun3, Dok-Hyun Yoon5, Keon Uk Park6, Se-Hoon Lee7, Yoon Woo Koh8, Se Hun Kim8, Eun Chang Choi8, Hye Ryun Kim1, Hyo Song Kim1, Joo Hang Kim1, Byoung Chul Cho1. 1Yonsei Cancer Center, Seoul, Korea, Republic of; 2Department of Pathology, Yonsei University College of Medicine, Seoul, Korea, Republic of; 3Samsung Medical Center, Seoul, Korea, Republic of; 4Kyungpook National University Hospital, Seoul, Korea, Republic of; 5Asan Medical Center, Seoul, Korea, Republic of; 6Keimyung University, Seoul, Korea, Republic of; 7Seoul National University, Seoul, Korea, Republic of; 8Department of Otorhinolaryngology, Yonsei University College of Medicine, Seoul, Korea, Republic of
Discussant
Monday, Apr 07, 2014, 11:50 AM -12:00 PM
Barbara A. Burtness. Fox Chase Cancer Ctr., Philadelphia, PA
CT230: Pediatric phase 1 trial of moxetumomab pasudotox: Activity in chemotherapy refractory acute lymphoblastic leukemia (ALL)
Monday, Apr 07, 2014, 12:00 PM -12:20 PM
Alan S. Wayne1, Nirali N. Shah2, Deepa Bhojwani3, Lewis B. Silverman4, James A. Whitlock5, Maryalice Stetler-Stevenson6, Robert J. Kreitman7, Trishna Goswami8, Ramy Ibrahim8, Ira Pastan7. 1Children's Hospital Los Angeles, University of Southern California, Los Angeles, CA; 2Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, MD; 3Oncology, St. Jude Children's Research Hospital, Memphis, TN; 4Pediatric Oncology, Dana-Farber Cancer Institute/Boston Children's Hospital, Boston, MA; 5Hematology/Oncology, The Hospital for Sick Children, Department of Pediatrics, University of Toronto, Toronto, ON, Canada; 6Laboratory of Pathology, CCR, National Cancer Institute, NIH, Bethesda, MD; 7Laboratory of Molecular Biology, CCR, National Cancer Institute, NIH, Bethesda, MD; 8MedImmune, Gaithersburg, MD
Discussant
Monday, Apr 07, 2014, 12:20 PM -12:30 PM
Terzah M. Horton. Baylor College of Medicine Cancer Ctr., Houston, TX